Jade Biosciences (JBIO) Gains from Sales and Divestitures (2023 - 2026)
Jade Biosciences posted quarterly Gains from Sales and Divestitures of $32331.0 for Q1 2026, down 81.82% on a QoQ basis from $177820.0 in Q4 2025.
Jade Biosciences (JBIO) has 4 years of Gains from Sales and Divestitures data on file, last reported at $32331.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $32331.0; the trailing twelve-month figure through Mar 2026 stood at $32331.0 (changed N/A YoY), and the FY2025 full-year result was $177820.0, up 3137.8% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $32331.0, down from $177820.0 in the prior quarter.
- Across five years, Gains from Sales and Divestitures topped out at $9.9 million in Q4 2023 and bottomed at $815.0 in Q2 2023.
- The 4-year median for Gains from Sales and Divestitures is $6127.0 (2023), against an average of $937853.5.
- The widest annual swing landed in 2024, when Gains from Sales and Divestitures sank 99.94%; it then soared 3137.8% in 2025.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $9.9 million in 2023, then tumbled by 99.94% to $5492.0 in 2024, then jumped by 3137.8% to $177820.0 in 2025, then sank by 81.82% to $32331.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $32331.0 (Q1 2026), $177820.0 (Q4 2025), and $145489.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Jade Biosciences | 1.06 Bn | 1.06 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32,331.00 |
| Mar 31, 2026 | 32,331.00 |
| Dec 31, 2025 | 177,820.00 |
| Dec 31, 2025 | 177,820.00 |
| Sep 30, 2025 | 145,489.00 |
| Sep 30, 2025 | 145,489.00 |
| Jun 30, 2025 | 21,554.00 |
| Jun 30, 2025 | 21,554.00 |
| Dec 31, 2024 | 5,492.00 |
| Dec 31, 2024 | 5,492.00 |
| Sep 30, 2024 | 5,492.00 |
| Sep 30, 2024 | 5,492.00 |
| Jun 30, 2024 | 5,492.00 |
| Jun 30, 2024 | 5,492.00 |
| Mar 31, 2024 | 2,776.00 |
| Mar 31, 2024 | 2,776.00 |
| Dec 31, 2023 | 9.91 Mn |
| Dec 31, 2023 | 9.91 Mn |
| Sep 30, 2023 | 6,127.00 |
| Sep 30, 2023 | 6,127.00 |
| Jun 30, 2023 | 815.00 |
| Jun 30, 2023 | 815.00 |